“When there are allegations of misconduct, they are thoroughly investigated, and appropriate action is taken if such allegations are proven true,” the Bureau of Prisons told the newspaper. “This allegation is currently under investigation.”
Mr. Shkreli gained notoriety for inflating the price of a lifesaving anti-infection drug more than fiftyfold. The move, paired with his lack of remorse, earned Mr. Shkreli the nickname “pharma bro.”
Mr. Shkrel, who is serving a seven-year prison sentence for defrauding investors, is just 16 months into his sentence. The fraud is unrelated his hiking of the drug price.
The Wall Street Journal reported last week that even from behind bars, he continues to call the shots at Phoenixus AG, the rebranded name of his pharmaceutical company.
While incarcerated, Mr. Shkreli reportedly called his handpicked chief executive to fire him, phoned in advice to company officials and tried to buy shares from existing shareholders.
Controlling a business and having a cellphone while serving a prison sentence is illegal. If convicted, Mr. Shkreli could receive another year in prison and a fine.
Read the full report here.
More articles on pharmacy:
Bristol-Myers urges shareholders to support Celgene takeover
Novartis to pay $23M to settle claims it used charity payments as kickbacks
Martin Shkreli reportedly running his pharma company from prison
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.